Get started
Author

Sarah K. Jacques

Observed names: Jacques, Sarah K, S.K. Jacques, Sarah Jacques
ORCID: 0009-0002-6213-025X
Observed ORCID: 0009-0002-6213-025X
OpenAlex ID: A5080886404
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
2024 · Sarah K. Jacques, Janet McKeown, et al. · European Journal of Cancer · 25
Characteristics and outcomes of oncology unit patients requiring admission to an Australian intensive care unit
2018 · Aaron C. Tan, Sarah K. Jacques, et al. · Internal Medicine Journal · 14
Complete response in a patient with stage IV adrenocortical carcinoma treated with adjuvant trans‐catheter arterial chemo‐embolization (TACE)
2017 · Eugene Wong, Sarah Jacques, et al. · Asia-Pacific Journal of Clinical Oncology · 12
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
2024 · Amelia M. Taylor, Janet McKeown, et al. · European Journal of Cancer · 11
Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapy.
2022 · Amelia M. Taylor, Claire Galea, et al. · Journal of Clinical Oncology · 6
Pembrolizumab‐induced auto‐immune type‐1 diabetes in a patient with metastatic melanoma
2018 · Zainab Reslan, Michael Bennett, et al. · Journal of Pharmacy Practice and Research · 5
PDF
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
2023 · Julia Lai-Kwon, Sarah Jacques, et al. · European Journal of Cancer · 2
809P Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
2022 · S.K. Jacques, J. McKeown, et al. · Annals of Oncology · 2
Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma.
2022 · Julia Elizabeth Lai-Kwon, Sarah Jacques, et al. · Journal of Clinical Oncology · 1
Small bowel obstruction incidence in Lu177 PRRT patients had no impact on overall survival
2025 · Sarah Jacques, Nicholas Skill, et al. · Endocrine Abstracts
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
2024 · Taylor, Amelia M, McKeown, Janet, et al. · Zurich Open Repository and Archive (University of Zurich)
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
2024 · Jacques, Sarah K, McKeown, Janet, et al. · Zurich Open Repository and Archive (University of Zurich)
Works count: 14
Citation count: 78
H-index: 5
I10-index: 4
Year
Topic
Type